Structure-activity relationship and biological evaluation of xanthine derivatives as PCSK9 inhibitors for the treatment of atherosclerosis

Identification and evaluation of a lipid-lowering small compound in preclinical models and in a Phase I trial

(2022) Jiang Wang et al.   Cell Metabolism

A small-molecule inhibitor of PCSK9 transcription ameliorates atherosclerosis through the modulation of FoxO1/3 and HNF1α

(2020) Xuelei Wang et al.   EBioMedicine

In Search for Genes Related to Atherosclerosis and Dyslipidemia Using Animal Models

(2020) Anastasia V. Poznyak et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Statin-Associated Autoimmune Myopathy: Current Perspectives

(2020) Eleni Tiniakou   Therapeutics and Clinical Risk Management

From Methylene Bridged Diindole to Carbonyl Linked Benzimidazoleindole: Development of Potent and Metabolically Stable PCSK9 Modulators

(2020) Haibo Xie et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Discovery of 2,3′-diindolylmethanes as a novel class of PCSK9 modulators

(2019) Gabrielle N. Winston-McPherson et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

The Global Burden of Cardiovascular Diseases and Risk Factors

(2019) George A. Mensah et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Comparative Effects of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibition and Statins on Postprandial Triglyceride-Rich Lipoprotein MetabolismHighlights

(2018) Dick C. Chan et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Small Molecule Inhibitors of the PCSK9·LDLR Interaction

(2018) Jaru Taechalertpaisarn et al.   JOURNAL OF THE AMERICAN CHEMICAL SOCIETY

Inhibiting Translation One Protein at a Time

(2017) Matthew D. Disney   TRENDS IN BIOCHEMICAL SCIENCES

PCSK9 deficiency results in increased ectopic fat accumulation in experimental models and in humans

(2017) Andrea Baragetti et al.   European Journal of Preventive Cardiology

Effects of PCSK9 Inhibition With Alirocumab on Lipoprotein Metabolism in Healthy HumansClinical Perspective

(2016) Gissette Reyes-Soffer et al.   CIRCULATION

Cost-effectiveness of PCSK9 Inhibitor Therapy in Patients With Heterozygous Familial Hypercholesterolemia or Atherosclerotic Cardiovascular Disease

(2016) Dhruv S. Kazi et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

PCSK9 R46L Loss-of-Function Mutation Reduces Lipoprotein(a), LDL Cholesterol, and Risk of Aortic Valve Stenosis

(2016) Anne Langsted et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

microRNA-185 modulates low density lipoprotein receptor expression as a key posttranscriptional regulator

(2015) Huajun Jiang et al.   ATHEROSCLEROSIS

Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events

(2015) Jennifer G. Robinson et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events

(2015) Marc S. Sabatine et al.   NEW ENGLAND JOURNAL OF MEDICINE

PCSK9R46L, Low-Density Lipoprotein Cholesterol Levels, and Risk of Ischemic Heart Disease

(2010) Marianne Benn et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY